About one third of all medicine binds to the same type of receptor in the human body. An estimated 3 percent of the population have receptors of this type that are so genetically different that they are predisposed to altered, ineffective or adverse responses to medicine, a new study from the University of Copenhagen and the MRC Laboratory of Molecular Biology in Cambridge shows.
Drug discovery could be significantly accelerated thanks to a new high precision machine-learning model, developed by an international collaboration of researchers, including the University of Warwick.
Scientists have created computationally designed protein assemblies, that display some functions normally associated with living things, in the search for ways to transport therapeutic cargo into specific types of cells without using viruses as vehicles. These encapsulate their own RNA genomes and evolve new traits in complex environments. They are synthetic versions of the protein shells that viruses use to protect and deliver materials. The synthetic proteins evolved better RNA packaging, resistance against degrading enzymes in blood and longer circulation time.
Survival benefits of many cancer drug combinations are not due to drug synergy, but to a form of "bet hedging." Combination treatment gives each patient multiple chances of responding to at least one drug, increasing measures of survival within patient populations. Findings suggest new ways to interpret clinical trial data, identify truly synergistic drug pairings and improve the design of combination therapies.
A new methodology enables the investigation of a large number of structurally conserved enzymes belonging to the Fe(II)/2-oxoglutarate-dependent dioxygenase superfamily.
The rare, chronic, autosomal-recessive lysosomal storage disease Niemann-Pick disease type C1 (NPC1) is characterized by progressively debilitating and ultimately fatal neurological manifestations. There is an urgent need for disease-modifying therapies that address NPC1 neurological pathophysiology; and passage through the blood-brain barrier represents an important consideration for novel NPC1 drugs.
A new addition to a series of articles that focus on important topics related to the development of oligonucleotide therapeutics presents an in-depth look at the identification, characterization, and reporting of product-related impurities.
A new study shows that attaching antibody-like RNA nanoparticles to microvesicles can deliver effective RNA therapeutics specifically to cancer cells. Researchers used RNA nanotechnology to apply the RNA nanoparticles and control their orientation. The microscopic, therapy-loaded extracellular vesicles successfully targeted three types of cancer in animal models. The findings could lead to a new generation of anticancer drugs that use siRNA, microRNA and other RNA-interference technologies.
SBP and Technion Institute researchers have SHARPIN-ed their knowledge of how a malicious form of a protein drives the formation of melanoma through modulation of the PRMT5 pathway. The new research was published in the Journal of Clinical Investigation.
It took several years, but a research team headed by Professor Jens Nielsen at Chalmers University of Technology has finally succeeded in mapping out the complex metabolism of yeast cells. The breakthrough, recently published in an article in Nature Communications, means a huge step forward in the potential to more efficiently produce protein therapies for diseases such as cancer.